Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy.

Lowery CD, Blosser W, Dowless M, Renschler M, Perez LV, Stephens J, Pytowski B, Wasserstrom H, Stancato LF, Falcon B.

Oncotarget. 2019 Sep 17;10(53):5523-5533. doi: 10.18632/oncotarget.27148. eCollection 2019 Sep 17.

2.

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models.

Lowery CD, Dowless M, Renschler M, Blosser W, VanWye AB, Stephens JR, Iversen PW, Lin AB, Beckmann RP, Krytska K, Cole KA, Maris JM, Hawkins DS, Rubin BP, Kurmasheva RT, Houghton PJ, Gorlick R, Kolb EA, Kang MH, Reynolds CP, Erickson SW, Teicher BA, Smith MA, Stancato LF.

Clin Cancer Res. 2019 Apr 1;25(7):2278-2289. doi: 10.1158/1078-0432.CCR-18-2728. Epub 2018 Dec 18.

PMID:
30563935
3.

Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling.

Dowless M, Lowery CD, Shackleford T, Renschler M, Stephens J, Flack R, Blosser W, Gupta S, Stewart J, Webster Y, Dempsey J, VanWye AB, Ebert P, Iversen P, Olsen JB, Gong X, Buchanan S, Houghton P, Stancato L.

Clin Cancer Res. 2018 Dec 1;24(23):6028-6039. doi: 10.1158/1078-0432.CCR-18-1256. Epub 2018 Aug 21.

PMID:
30131386
4.

18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancer.

Korn RL, Von Hoff DD, Borad MJ, Renschler MF, McGovern D, Curtis Bay R, Ramanathan RK.

Cancer Imaging. 2017 Aug 3;17(1):23. doi: 10.1186/s40644-017-0125-5.

6.

Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study.

Kunzmann V, Ramanathan RK, Goldstein D, Liu H, Ferrara S, Lu B, Renschler MF, Von Hoff DD.

Pancreas. 2017 Feb;46(2):203-208. doi: 10.1097/MPA.0000000000000742.

7.

Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Diabetes.

Hirsh V, Ko A, Pilot R, Renschler MF, Socinski MA.

Clin Lung Cancer. 2016 Sep;17(5):367-374. doi: 10.1016/j.cllc.2016.04.002. Epub 2016 Apr 22.

8.

Erratum to: 'Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.

Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S, Nabholtz JM, O'Shaughnessy J, Beck RM, Ko A, Renschler MF, Barton D, Harbeck N.

Trials. 2016 Feb 3;17:63. doi: 10.1186/s13063-016-1195-6. No abstract available.

9.

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.

Yardley DA, Brufsky A, Coleman RE, Conte PF, Cortes J, Glück S, Nabholtz JM, O'Shaughnessy J, Beck RM, Ko A, Renschler MF, Barton D, Harbeck N.

Trials. 2015 Dec 16;16:575. doi: 10.1186/s13063-015-1101-7. Erratum in: Trials. 2016;17:63.

10.

A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma.

Hersh EM, Del Vecchio M, Brown MP, Kefford R, Loquai C, Testori A, Bhatia S, Gutzmer R, Conry R, Haydon A, Robert C, Ernst S, Homsi J, Grob JJ, Kendra K, Agarwala SS, Li M, Clawson A, Brachmann C, Karnoub M, Elias I, Renschler MF, Hauschild A.

Ann Oncol. 2015 Nov;26(11):2267-74. doi: 10.1093/annonc/mdv324. Epub 2015 Sep 26.

11.

A proposed approach for analyzing post-study therapy effect in survival analysis.

Luo X, Li M, Wu C, Xu Q, Chen G, Dornseif BE, Renschler MF, Koch G.

J Biopharm Stat. 2016;26(4):790-800. doi: 10.1080/10543406.2015.1074916. Epub 2015 Aug 6.

PMID:
26247582
12.

Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel.

Langer CJ, Hirsh V, Okamoto I, Lin FJ, Wan Y, Whiting S, Ong TJ, Renschler MF, Botteman MF.

Br J Cancer. 2015 Jun 30;113(1):20-9. doi: 10.1038/bjc.2015.181. Epub 2015 Jun 2.

13.

Soluble VE-cadherin is involved in endothelial barrier breakdown in systemic inflammation and sepsis.

Flemming S, Burkard N, Renschler M, Vielmuth F, Meir M, Schick MA, Wunder C, Germer CT, Spindler V, Waschke J, Schlegel N.

Cardiovasc Res. 2015 Jul 1;107(1):32-44. doi: 10.1093/cvr/cvv144. Epub 2015 May 14.

PMID:
25975259
14.

Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: analysis of safety and efficacy in patients with renal impairment.

Langer CJ, Hirsh V, Ko A, Renschler MF, Socinski MA.

Clin Lung Cancer. 2015 Mar;16(2):112-20. doi: 10.1016/j.cllc.2014.09.003. Epub 2014 Sep 30.

PMID:
25572008
15.

Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.

von Pawel J, Jotte R, Spigel DR, O'Brien ME, Socinski MA, Mezger J, Steins M, Bosquée L, Bubis J, Nackaerts K, Trigo JM, Clingan P, Schütte W, Lorigan P, Reck M, Domine M, Shepherd FA, Li S, Renschler MF.

J Clin Oncol. 2014 Dec 10;32(35):4012-9. doi: 10.1200/JCO.2013.54.5392. Epub 2014 Nov 10.

PMID:
25385727
16.

Albumin-bound paclitaxel plus gemcitabine in pancreatic cancer.

Von Hoff DD, Goldstein D, Renschler MF.

N Engl J Med. 2014 Jan 30;370(5):479-80. doi: 10.1056/NEJMc1314761. No abstract available.

PMID:
24476438
17.

Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer.

Hirsh V, Okamoto I, Hon JK, Page RD, Orsini J, Sakai H, Zhang H, Renschler MF, Socinski MA.

J Thorac Oncol. 2014 Jan;9(1):83-90. doi: 10.1097/JTO.0000000000000011.

18.

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF.

N Engl J Med. 2013 Oct 31;369(18):1691-703. doi: 10.1056/NEJMoa1304369. Epub 2013 Oct 16.

19.

Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer.

Socinski MA, Okamoto I, Hon JK, Hirsh V, Dakhil SR, Page RD, Orsini J, Yamamoto N, Zhang H, Renschler MF.

Ann Oncol. 2013 Sep;24(9):2390-6. doi: 10.1093/annonc/mdt235. Epub 2013 Jul 10.

PMID:
23842283
20.

Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors.

Chen N, Chawla SP, Chiorean EG, Read WL, Gorbaty M, Mita AC, Yung L, Bryan P, McNally R, Renschler MF, Sharma S.

Cancer Chemother Pharmacol. 2013 Apr;71(4):1083-94. doi: 10.1007/s00280-013-2093-1. Epub 2013 Feb 12.

PMID:
23400695
21.

Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer.

Socinski MA, Langer CJ, Okamoto I, Hon JK, Hirsh V, Dakhil SR, Page RD, Orsini J, Zhang H, Renschler MF.

Ann Oncol. 2013 Feb;24(2):314-21. doi: 10.1093/annonc/mds461. Epub 2012 Nov 2.

PMID:
23123509
22.

Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial.

Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, Iglesias JL, Renschler MF.

J Clin Oncol. 2012 Jun 10;30(17):2055-62. doi: 10.1200/JCO.2011.39.5848. Epub 2012 Apr 30.

PMID:
22547591
23.

90Sr therapy for oral squamous cell carcinoma in two cats.

Nagata K, Selting KA, Cook CR, Renschler M, Lattimer JC.

Vet Radiol Ultrasound. 2011 Jan-Feb;52(1):114-7.

PMID:
21322398
24.

Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.

Jotte R, Conkling P, Reynolds C, Galsky MD, Klein L, Fitzgibbons JF, McNally R, Renschler MF, Oliver JW.

J Clin Oncol. 2011 Jan 20;29(3):287-93. doi: 10.1200/JCO.2010.29.8851. Epub 2010 Dec 6.

PMID:
21135284
25.

Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer.

Ettinger DS, Jotte R, Lorigan P, Gupta V, Garbo L, Alemany C, Conkling P, Spigel DR, Dudek AZ, Shah C, Salgia R, McNally R, Renschler MF, Oliver JW.

J Clin Oncol. 2010 May 20;28(15):2598-603. doi: 10.1200/JCO.2009.26.7682. Epub 2010 Apr 12.

PMID:
20385980
26.

Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial.

Mehta MP, Shapiro WR, Phan SC, Gervais R, Carrie C, Chabot P, Patchell RA, Glantz MJ, Recht L, Langer C, Sur RK, Roa WH, Mahe MA, Fortin A, Nieder C, Meyers CA, Smith JA, Miller RA, Renschler MF.

Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1069-76. doi: 10.1016/j.ijrobp.2008.05.068. Epub 2008 Oct 30.

PMID:
18977094
27.

Relationship between neurocognitive function and quality of life after whole-brain radiotherapy in patients with brain metastasis.

Li J, Bentzen SM, Li J, Renschler M, Mehta MP.

Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):64-70. doi: 10.1016/j.ijrobp.2007.09.059.

PMID:
18406884
28.
29.

Comments about the prospective randomized trial by Aoyama et al.

Patchell RA, Regine WF, Renschler M, Loeffler JS, Sawaya R, Chin LS, Andrews DW.

Surg Neurol. 2006 Nov;66(5):459-60. No abstract available.

PMID:
17084184
30.

Population pharmacokinetics of motexafin gadolinium in adults with brain metastases or glioblastoma multiforme.

Miles DR, Smith JA, Phan SC, Hutcheson SJ, Renschler MF, Ford JM, Boswell GW.

J Clin Pharmacol. 2005 Mar;45(3):299-312.

PMID:
15703365
31.

The emerging role of reactive oxygen species in cancer therapy.

Renschler MF.

Eur J Cancer. 2004 Sep;40(13):1934-40. Review.

PMID:
15315800
32.

Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial.

Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T, Kunkler I, Caudrelier JM, Eisenberg PD, Meerwaldt J, Siemers R, Carrie C, Gaspar LE, Curran W, Phan SC, Miller RA, Renschler MF.

J Clin Oncol. 2004 Jan 1;22(1):157-65.

PMID:
14701778
33.

Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases.

Mehta MP, Rodrigus P, Terhaard CH, Rao A, Suh J, Roa W, Souhami L, Bezjak A, Leibenhaut M, Komaki R, Schultz C, Timmerman R, Curran W, Smith J, Phan SC, Miller RA, Renschler MF.

J Clin Oncol. 2003 Jul 1;21(13):2529-36.

PMID:
12829672
34.

Neurocognitive and functional assessment of patients with brain metastases: a pilot study.

Herman MA, Tremont-Lukats I, Meyers CA, Trask DD, Froseth C, Renschler MF, Mehta MP.

Am J Clin Oncol. 2003 Jun;26(3):273-9.

PMID:
12796600
35.

Lead-in phase to randomized trial of motexafin gadolinium and whole-brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points.

Mehta MP, Shapiro WR, Glantz MJ, Patchell RA, Weitzner MA, Meyers CA, Schultz CJ, Roa WH, Leibenhaut M, Ford J, Curran W, Phan S, Smith JA, Miller RA, Renschler MF.

J Clin Oncol. 2002 Aug 15;20(16):3445-53.

PMID:
12177105
36.

Multicenter phase Ib/II trial of the radiation enhancer motexafin gadolinium in patients with brain metastases.

Carde P, Timmerman R, Mehta MP, Koprowski CD, Ford J, Tishler RB, Miles D, Miller RA, Renschler MF.

J Clin Oncol. 2001 Apr 1;19(7):2074-83.

PMID:
11283141
37.

Photoangioplasty for human peripheral atherosclerosis: results of a phase I trial of photodynamic therapy with motexafin lutetium (Antrin).

Rockson SG, Kramer P, Razavi M, Szuba A, Filardo S, Fitzgerald P, Cooke JP, Yousuf S, DeVault AR, Renschler MF, Adelman DC.

Circulation. 2000 Nov 7;102(19):2322-4.

PMID:
11067782
38.

In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer.

Miller RA, Woodburn K, Fan Q, Renschler MF, Sessler JL, Koutcher JA.

Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):981-9.

PMID:
10571206
39.

Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: preliminary results in brain metastases.

Viala J, Vanel D, Meingan P, Lartigau E, Carde P, Renschler M.

Radiology. 1999 Sep;212(3):755-9.

PMID:
10478243
40.

A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging.

Rosenthal DI, Nurenberg P, Becerra CR, Frenkel EP, Carbone DP, Lum BL, Miller R, Engel J, Young S, Miles D, Renschler MF.

Clin Cancer Res. 1999 Apr;5(4):739-45.

41.

Identification of peptide ligands for the antigen binding receptor expressed on human B-cell lymphomas.

Renschler MF, Dower WJ, Levy R.

Methods Mol Biol. 1998;87:209-34. No abstract available.

PMID:
9523274
43.

Synthetic peptide ligands of the antigen binding receptor induce programmed cell death in a human B-cell lymphoma.

Renschler MF, Bhatt RR, Dower WJ, Levy R.

Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3623-7.

44.
45.

Avoiding needle-stick injuries in the emergency department.

Renschler MF.

Am J Emerg Med. 1992 May;10(3):267-8. No abstract available.

PMID:
1586445
46.

Avoiding exposure to HIV by needle stick.

Renschler MF.

N Engl J Med. 1990 Aug 30;323(9):611-2. No abstract available.

PMID:
2381449

Supplemental Content

Loading ...
Support Center